On December 14th local time, Novo Nordisk announced that all regulatory delivery conditions related to its major shareholder Novo Nordisk's $16.5 billion acquisition of US contract pharmaceutical company Catalent have been met, and both parties are now free to complete the transaction. Novo Nordisk will subsequently acquire three Catalent manufacturing bases from Novo Nordisk. Novo Nordisk expects the acquisition to be completed in the coming days.
In February of this year, Novo Holding announced that it would acquire Contante in an all cash transaction, with a total corporate value of $16.5 billion including debt. As part of the transaction, Novo Nordisk will acquire Contante's three bottling plants located in Arnany, Italy, Brussels, Belgium, and Bloomington, Indiana, USA from Novo Holding for a prepayment of $11 billion.